Geoff Kau – Co-GM & CSO, Ping An Smart City, China
Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City,…
Yangtze River Pharmaceutical Group is a Chinese multinational pharmaceutical corporation headquartered in Taizhou, Jiangsu Province in the People’s Republic of China, and with its research headquarters in Shanghai. It is one of the Asia’s largest pharmaceutical companies by revenues, and was listed in 2014 as being China’s second largest pharmaceutical manufacturer, and leading company for technological and entrepreneurial innovation.
Founded in 1971, the Yangtze River Pharmaceutical Group started as a local firm providing drugstores and hospitals with vitamin supplements and pain medication. For much of its early existence, profit margins were low due to the YRPG’s inability to expand a fledgeling sales network past a local level. This changed at the end of the 20th century when sweeping economic and medical reforms placed an ever-increasing demand on quality drug production.[5] Located in a prime location between the major cities of Shanghai, Suzhou, and Hangzhou, the YRPG quickly expanded its business profile. The group has experienced significant growth in the past decade, having quadrupled their net income between 2003-2010.[1] In the fiscal year 2014, board shareholders received a record 560% return on investment, and company assets rapidly expanded.[1] The company also hosts 22 subsidiary firms across Asia and has exploratory ventures in Europe, Canada, and the United States.
Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City,…
Charles Bark, CEO and founder of HiNounou, shares the touching personal story of what inspired him to establish HiNounou as a complete remote healthcare solution package for elderly people; how…
China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
Wang Wei of Winhealth Pharma, one of China’s leading contract development and commercialisation organisations, outlines the rationale behind the company’s formation, how its business model is changing to keep up…
Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO in 2008, before launching a…
Eric Bouteiller outlines the paradigm shift occurring in China around rare diseases and how the country has the potential to lead the global pharmaceutical industry in this vital area. …
Download our latest pharma country report on China here 2019 is a landmark year for China, marking not only the 70th anniversary of the establishment of the People’s Republic…
Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which…
Mike Braun, partner at Deloitte China, shares his perspectives on the recent China reforms, the strong presence of Deloitte within China as a consulting firm with a DNA in professional…
On 21 September 2019, the China Pharmaceutical International Innovation and Research Development Association (PhIRDA), officially inaugurated the 4th China Biomed International Innovation Conference (CBIIC), at the Suzhou International Convention and…
2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having been established that year, celebrating its 40th anniversary…
See our Cookie Privacy Policy Here
